Related Experiment Video
Updated: Nov 17, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Population impact of different hypertension management guidelines based on the prospective population-based Heinz
Janine Gronewold1, Rene Kropp2, Nils Lehmann3
1Department of Neurology, University Hospital Essen, Essen, Germany janine.gronewold@uk-essen.de.
Insights
The ACC/AHA 2017 hypertension guideline recommends medication for more people, who then show higher cardiovascular event rates. Further trials are needed to confirm if this stricter guideline reduces cardiovascular disease.
Area of Science:
- Cardiology
- Public Health
- Epidemiology
Background:
- Hypertension guidelines vary significantly across different societies.
- The ACC/AHA 2017 guideline recommends antihypertensive medication for a larger population segment compared to previous guidelines.
- The comparative impact of different hypertension guidelines on cardiovascular risk has not been systematically evaluated.
Purpose of the Study:
- To compare the prevalence of antihypertensive medication recommendations across major international hypertension guidelines.
- To assess the association between guideline-based medication recommendations and incident cardiovascular events.
Main Methods:
- The Heinz Nixdorf Recall study population (n=3092) without baseline medication was analyzed.
- Prevalence of medication recommendation was compared using ACC/AHA 2017, JNC7, ESH/ESC 2013/2018, and WHO/ISH 2003/2020 guidelines.
- Incident cardiovascular events were compared between participants with and without medication recommendations over a 5-year follow-up.
Main Results:
- The ACC/AHA 2017 guideline identified the highest proportion of individuals (45.8%) for medication.
- Compared to other guidelines, ACC/AHA 2017 recommended medication for significantly more participants.
- Participants recommended for medication by ACC/AHA 2017 had a higher 5-year incidence of cardiovascular events (2.5% vs 1.1%, p=0.003).
Conclusions:
- The ACC/AHA 2017 guideline identifies a higher-risk population for antihypertensive medication.
- A higher incidence of cardiovascular events was observed in those recommended for medication under the ACC/AHA 2017 guideline.
- Randomized controlled trials are warranted to determine if implementing the ACC/AHA 2017 guideline reduces cardiovascular disease.
Objective:
Hypertension guidelines strongly differ between societies. The current American College of Cardiology/American Heart Association (ACC/AHA) guideline recommends higher proportions of the general population for antihypertensive medication than the previous American and European guidelines. How cardiovascular risk differs between persons with and without antihypertensive medication recommendation has not been examined. Additionally, the population impact of American, European and international guidelines has not been compared systematically within the same study population.
Methods:
We compared the prevalence of antihypertensive medication recommendation according to the American (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 7 (JNC7), ACC/AHA 2017), European (European Society of Hypertension (ESH)/European Society of Cardiology (ESC) 2013/2018), and international (WHO/International Society of Hypertension (ISH) 2003, ISH 2020) guidelines in 3092 participants of the population-based Heinz Nixdorf Recall study not taking antihypertensive medication at the baseline examination (58.1±7.5 years, 48.7% males). We furthermore compared incident cardiovascular events during the 5-year follow-up between participants with and without antihypertensive medication recommendation.
Results:
The ACC/AHA 2017 guideline recommended the highest percentage of participants for antihypertensive medication (45.8%) compared with the JNC7 (37.2%), ESH/ESC 2013 (17.8%), ESC/ESH 2018 (26.7%), WHO/ISH 2003 (20.3%) or ISH 2020 (25.0%) guidelines. Participants with antihypertensive medication recommendation according to the ACC/AHA 2017 guideline had a significantly higher incidence of cardiovascular events during the 5-year follow-up compared with participants without this recommendation (2.5% vs 1.1%, p=0.003).
Conclusions:
Our results call for randomised controlled trials to investigate whether applying the stricter ACC/AHA 2017 recommendation leads to a reduction in cardiovascular disease.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension I: Introduction
Hypertension and Regulation of Blood Pressure
Errors occurring during blood pressure monitoring
Several factors...

